Skip to main content

4 Result(s)

within Ahmed Abbas Suleiman Remove this filter

and

  1. Article

    A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients

    Treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used for treating non-small-cell lung cancer (NSCLC) and other cancers, is frequently associated with adverse events (AE)...

    Ahmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler… in The AAPS Journal (2015)

    Download PDF (761 KB) View Article

  2. No Access

    Article

    A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole

    Accurate predictions of cytochrome P450 (CYP) 3A-mediated drug-drug interactions (DDIs) account for dynamic changes of CYP3A activity at both major expression sites (liver and gut wall) by considering the full...

    Sebastian Frechen, Lisa Junge, Teijo I. Saari… in Clinical Pharmacokinetics (2013)

  3. No Access

    Article

    Modeling NSCLC Progression: Recent Advances and Opportunities Available

    Non-small cell lung cancer (NSCLC) is one of the leading causes of death around the world with an estimated 5-year relative survival rate of 16% at diagnosis. Development of drugs treating NSCLC is not easy, a...

    Ahmed Abbas Suleiman, Lucia Nogova, Uwe Fuhr in The AAPS Journal (2013)

  4. No Access

    Article

    Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials

    The likelihood of detecting a therapeutic signal of an effective drug for schizophrenia is impeded by a high placebo effect and by high dropout of patients. Several unsuccessful trials of schizophrenia, at lea...

    Venkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson… in Clinical Pharmacokinetics (2012)